About TearClear
TearClear is a company based in Copley Township (United States) founded in 2015. TearClear has raised $31.98 million across 5 funding rounds from investors including Falcon Vision, Visionary Ventures and Bluestem. TearClear operates in a competitive market with competitors including Qlaris Bio, 4B Technologies, Aria Pharmaceuticals, Mannin Research and Altheos, among others.
- Headquarter Copley Township, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Tearclear Corp.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$31.98 M (USD)
in 5 rounds
-
Latest Funding Round
$5.9 M (USD), Debt – Conventional
Aug 16, 2022
-
Investors
Falcon Vision
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of TearClear
TearClear has successfully raised a total of $31.98M across 5 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $5.9 million completed in August 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in TearClear
TearClear has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Falcon Vision, Visionary Ventures and Bluestem.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A venture capital fund focused on life sciences investments.
|
Locked | Locked | Locked | |
|
Bluestem is recognized as a Midwest private equity company.
|
Locked | Locked | Locked | |
|
Flying L Partners is focused on ophthalmic sector investments.
|
Locked | Locked | Locked |
Investor details for TearClear
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by TearClear
Investment portfolio details for TearClear
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - TearClear
Detailed financials for TearClear
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Tearclear Comparisons
Peer comparison for TearClear
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of TearClear
TearClear operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Qlaris Bio, 4B Technologies, Aria Pharmaceuticals, Mannin Research and Altheos, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-based technology is developed for treating ophthalmic diseases.
|
|
| Locked | Locked | Locked |
Drugs for neurological disorders including ALS and Alzheimer's are developed.
|
|
| Locked | Locked | Locked |
Develops innovative drug technologies for multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for vascular diseases are developed by Mannin Research.
|
|
| Locked | Locked | Locked |
Focuses on R&D and manufacturing of drugs for various therapeutic areas.
|
Detailed competitors of TearClear
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Tearclear
Complete news archive for TearClear
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TearClear
TearClear was founded in 2015 and raised its 1st funding round 2 years after it was founded.
TearClear is headquartered in Copley Township, United States. It is registered at Copley Township, Ohio, United States.
TearClear is a funded company, having raised a total of $31.98M across 5 funding rounds to date.
TearClear was founded in 2015 in Copley Township, United States, within the biotechnology sector focused on ophthalmic treatments. A chemical filter technology is being developed to remove benzalkonium chloride at the point of drug instillation, enabling safe preservation of multi-dose products for glaucoma, dry-eye, and allergic conjunctivitis therapies until application. Operations center on advancing this delivery method for topical ophthalmic drugs.
TearClear's top competitors include Qlaris Bio, 4B Technologies and Visiox Pharma.
TearClear has 4 investors. Key investors include Falcon Vision, Visionary Ventures, Bluestem, and Flying L Partners.